DCM
NKTR icon

Deuterium Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Deuterium Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,000
Closed -$1.3M – 26
2026
Q1 		$1.3M Sell
18,000
-19,349
-52% -$1.1M 1.51% 15
2025
Q4 		$1.58M Hold
37,349
– – 2.29% 9
2025
Q3 		$2.13M Hold
37,349
– – 3.08% 7
2025
Q2 		$965K Hold
37,349
– – 1.81% 9
2025
Q1 		$381K Buy
+37,349
New +$488K 0.85% 14

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deuterium Capital Management's NKTR Position: Q2 2026 in Review

Deuterium Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 18,000 shares — an estimated $1.3M sold.

Deuterium Capital Management first reported a position in NKTR in Q1 2025 and held it in 5 quarters. The position peaked at $2.13M in Q3 2025. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Deuterium Capital Management reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Deuterium Capital Management sold 18,000 Nektar Therapeutics shares in Q2 2026, an estimated $1.3M.
  • Deuterium Capital Management first reported a position in Nektar Therapeutics in Q1 2025 and held it in 5 quarters.
  • Deuterium Capital Management's Nektar Therapeutics position peaked at $2.13M in Q3 2025.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Deuterium Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.